Mannin Research Inc.
  • Home
  • Team
  • Lead Technology
  • News
  • Contact Us

biotechnology

  • Mannin and Cyclica Enter JV to Rapidly Develop COVID-19 Drugs

    Mannin-Cyclica JV to rapidly develop drugs to treat COVID-19 patients using the Tie2 receptor expertise of Mannin and Cyclica’s AI-augmented drug discovery platform The projects will include small molecule treatments to treat infectious diseases including COVID-19 and influenza Toronto, Canada and Leipzig, Germany, April 20th, 2020 – Mannin Research has entered a joint venture (JV) between Mannin GmbH, a German Mannin subsidiary, and Cyclica Inc. The Mannin – Cyclica...

Pages

  • Contact Us
  • Home
  • Lead Technology
  • News
  • Team

Recent Posts

  • Mannin and Cyclica Enter JV to Rapidly Develop COVID-19 Drugs
  • Mannin Research Inc. Presents Data Showing Potential Treatment to Protect Kidney in Acute Kidney Injury Using Mannin Tie2 Activator

Categories

  • Archives
  • News
Mannin Research Inc.
Mannin Research Inc. is a biotechnology company leading the development of a new class of vascular therapeutics.
  • 629 Eastern Avenue, Suite C300 Toronto, Ontario M4M 1E4
  • (416) 775 9767
  • @info@mannin.ca

Recent Tweets

RECENT POSTS

  • Mannin and Cyclica Enter JV to Rapidly Develop COVID-19 Drugs
  • Mannin Research Inc. Presents Data Showing Potential Treatment to Protect Kidney in Acute Kidney Injury Using Mannin Tie2 Activator
Mannin Research Inc., Copyright 2016, All Rights Reserved
  • Home
  • Team
  • Lead Technology
  • News
  • Contact Us